The FDA approved pembrolizumab (Keytruda, Merck) with chemoradiotherapy (CRT) for patients with FIGO 2014 stage III to IVA cervical cancer.
Efficacy was evaluated in KEYNOTE-A18, a multicenter, randomized, double-blind, placebo-controlled trial enrolling 1,060 patients with cervical cancer who had not previously received definitive surgery, radiation or systemic therapy. The trial included 596 patients with FIGO 2014 stage III to IVA disease and 462 patients with FIGO 2014 stage IB2 to IIB
JANUARY 17, 2024